Prostate Biopsy Market Size & Share Analysis - Growth Trends and Forecast (2027 - 2032)

The Prostate Biopsy Market is Segmented by Biopsy Type (Needle, Liquid), Guidance Technology (Ultrasound, MRI, MRI-US Fusion, Cognitive Fusion, CT-Guided, Others), Product Type (Needles, Guns and Instruments, Navigation Systems, Accessories, Others), End User (Hospitals, Ascs, Diagnostic Centers, Urology Clinics, Others), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts are in Terms of Value (USD).

Prostate Biopsy Market Size and Share

Prostate Biopsy Market Size
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Prostate Biopsy Market Analysis by Mordor Intelligence

The Prostate Biopsy Market size was valued at USD 2.04 billion in 2026 and is estimated to grow from USD 2.20 billion in 2027 to reach USD 3.18 billion by 2032, at a CAGR of 7.66% during the forecast period (2027-2032).

Rising prostate cancer diagnoses continue to drive demand for biopsy procedures, while active surveillance increases the need for follow-up testing among selected patients. The prostate biopsy market is shifting toward MRI-informed targeting, transperineal access, and workflows suitable for outpatient settings. New U.S. reimbursement codes for transperineal, in-bore MRI-guided, and MRI-ultrasound fusion procedures support investment in advanced guidance platforms. However, high equipment costs, limited MRI capacity, and shortages of trained radiologists and urologists may constrain adoption in lower-resource settings. The strongest near-term opportunities lie with suppliers offering targeted sampling, efficient workflows, and practical training support.

Key Report Takeaways

  • By biopsy type, prostate needle biopsy held 85.67% of the prostate biopsy market share in 2026, while prostate liquid biopsy is projected to grow at a 9.28% CAGR through 2032.
  • By guidance technology, ultrasound-guided biopsy accounted for 51.45% of the prostate biopsy market share in 2026, while MRI-ultrasound fusion-guided biopsy is projected to expand at a 10.12% CAGR through 2032.
  • By product type, biopsy needles held 55.67% of revenue in 2026, while biopsy guidance and navigation systems are projected to grow at an 11.23% CAGR through 2032.
  • By end user, hospitals accounted for 56.89% of revenue in 2026, while ambulatory surgical centers are projected to advance at a 10.45% CAGR through 2032.
  • By geography, North America held 39.88% of revenue in 2026, while Asia-Pacific is projected to expand at a 9.88% CAGR through 2032.

Note: Market numbers in this report are based on Mordor Intelligence's proprietary estimation framework, which combines nine months of actuals with Q4 projections for base year 2026.

Prostate Biopsy Market Segment Analysis

By Biopsy Type:

Needle Volumes Sustain Revenue While Liquid Biopsy Accelerates

Prostate needle biopsy held 85.67% of the prostate biopsy market share in 2026, as tissue histopathology remains critical for diagnosis, grading, and risk stratification. More than 1 million prostate biopsies are performed annually in the United States, supporting consistent demand for procedure-related consumables. The shift from transrectal to transperineal access is changing demand for guides, needle systems, and accessories. Suppliers offering solutions for both routes can maintain their market position as clinical practices evolve.

Prostate liquid biopsy is forecast to grow at a CAGR of 9.28% through 2032. FDA approval of IsoPSA in December 2025 and its inclusion in the NCCN 2025 Early Detection Guideline support its role in pre-biopsy risk stratification. Liquid biopsy remains an adjunct to tissue biopsy and also supports minimal residual disease detection and treatment-response monitoring. It may reduce low-value procedures while directing tissue biopsy demand toward cases requiring definitive confirmation.

Need more granular breakdown of segment shares?

Get tailored market insights for your requirements.

Prostate Biopsy Market Share by Biopsy Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

By Guidance Technology:

Ultrasound Anchors Volumes as Fusion Redefines Standards

Ultrasound-guided biopsy accounted for 51.45% of the prostate biopsy market size in 2026. Its established installed base, lower cost, and suitability for office-based settings support continued adoption across community urology practices. It remains important in regions with limited MRI access and for systematic sampling pathways. Ultrasound also serves as the procedural foundation for MRI-ultrasound fusion-guided targeted biopsy.

MRI-ultrasound fusion-guided biopsy is forecast to grow at a CAGR of 10.12% through 2032. The technology combines MRI findings with real-time ultrasound to improve targeting of suspicious lesions. A 2025 cohort study reported clinically significant cancer detection rates of 44.7% for transperineal cognitive fusion biopsy, compared with 25.6% for systematic biopsy. The new CPT structure provides a clearer economic foundation for facilities adopting advanced guidance pathways.

By Product Type:

Needles Lead Revenue but Navigation Systems Lead Growth

Biopsy needles held 55.67% of revenue in 2026 because every tissue-based procedure requires needle-based sample collection. This high-volume consumable role supports stable demand despite changes in guidance technologies. Manufacturers are focusing on improved sampling reliability, lower infection risk, and integration with imaging workflows. Infection-prevention features are becoming increasingly relevant as providers adopt transperineal and other risk-reduction approaches.

Biopsy guidance and navigation systems are forecast to expand at a CAGR of 11.23% through 2032. Clinical programs are investing in fusion and robotic platforms that support biopsy procedures and focal therapy planning. In July 2025, Philips received FDA 510(k) clearance for an updated UroNav system integrating pre-procedural MRI, real-time ultrasound, and focal therapy planning workflows. These platforms help standardize targeting, improve documentation, and support integrated clinical workflows.

Segment this market the way your business does.

Get tailored market insights for your requirements.

Prostate Biopsy Market Share by Product Type, 2026
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Prostate Biopsy Market Share by Product Type, 2026

By End User:

Hospitals Anchor Volume While ASCs Drive Structural Change

Hospitals accounted for 56.89% of revenue in 2026 because they manage a substantial share of complex and imaging-intensive biopsy procedures. They offer MRI capacity, coordinated radiology and urology teams, and anesthesia support when required. Academic centers are also establishing outpatient transperineal programs that reduce dependence on conventional operating room settings. Hospitals will remain central to challenging cases and advanced imaging pathways.

Ambulatory surgical centers are forecast to grow at a CAGR of 10.45% through 2032. Local-anesthetic transperineal biopsy reduces facility requirements for selected patients, while the 2026 reimbursement framework supports fusion and transperineal procedures in ASC settings. Diagnostic and imaging centers may expand their role in pre-biopsy MRI interpretation and coordinated in-office pathways. Compact systems that reduce reliance on external equipment can improve adoption across ASCs, imaging centers, and clinics.

Geography Analysis

North America

North America is projected to account for 39.88% of the prostate biopsy market share in 2026. The region has an age-standardized prostate cancer incidence rate of 80.82 per 100,000 population and performs more than 1 million prostate biopsies annually in the United States. The 2026 CPT code structure differentiates reimbursement for transrectal, transperineal, in-bore MRI-guided, and MRI-ultrasound fusion-guided procedures, supporting the shift toward targeted biopsies. FDA-cleared AI tools and Medicare coverage for IsoPSA support integrated diagnostic workflows and more targeted biopsy utilization. Compliance with FDA requirements and evolving payer policies remains critical, while Canada and Mexico offer additional growth opportunities as urology capacity expands.

Asia-Pacific

Asia-Pacific is forecast to expand at a CAGR of 9.88% from 2027 to 2032. Rising prostate cancer incidence in China, India, and South Korea, combined with broader screening coverage and healthcare investment, supports market growth. Japan’s aging male population drives demand for precise diagnostic pathways, while India and South Korea benefit from government-backed detection initiatives and expanding private hospital capacity. Uneven MRI access and specialist availability will influence adoption, sustaining demand for lower-cost ultrasound-guided procedures. Suppliers offering compact technologies, training, and flexible procurement models may gain a competitive advantage, although local registration and reimbursement requirements will continue to shape market entry.

Europe, South America, and the Middle East and Africa

European providers are increasingly aligning diagnostic practices with the 2026 EAU guidance on pre-biopsy MRI and targeted sampling. Germany’s S3 guideline recommends MRI-guided or MRI-fusion-guided biopsy for PI-RADS 3 or higher lesions, supporting reduced reliance on unnecessary systematic sampling. In South America, Brazil anchors demand as prostate cancer remains a significant cause of cancer mortality. The Middle East and Africa show varying levels of access, with GCC countries investing in advanced fusion platforms while underserved areas face limited diagnostic capacity. Portable, lower-cost systems may address late-diagnosis challenges, while infrastructure, reimbursement, and clinical training continue to shape market development.

Prostate Biopsy Market Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Market Concentration

Prostate Biopsy Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

The prostate biopsy market demonstrates moderate concentration, with multinational imaging companies competing alongside specialized needle, navigation, and procedure workflow providers. Siemens Healthineers, Koninklijke Philips, GE HealthCare, and Canon Medical offer imaging and guidance platforms, while Becton Dickinson, Argon Medical Devices, B. Braun, and Cook Group serve the high-volume consumables segment. KOELIS, Exact Imaging, Focal Healthcare, and Biobot Surgical provide integrated systems for ambulatory and office-based settings. Competition centers on workflow integration, targeted sampling accuracy, and support for biopsy and focal therapy planning.

AI integration remains a key product differentiation strategy. In April 2025, KOELIS announced a partnership with Bot Image to integrate its Trinity MRI fusion system with ProstatID AI for automated lesion detection, classification, and 3D contouring. Ibex and Quibim have used FDA clearances to position their software tools in pathology and MRI workflows, while Philips has advanced its FDA-cleared UroNav platform for navigation and focal therapy planning. These developments enhance the value of installed hardware by integrating imaging, targeting, and reporting processes. Smaller companies can also use partnerships to add AI capabilities without developing all components internally.

Transperineal system design represents another important competitive area. In July 2025, Exact Imaging transitioned to a direct U.S. sales model to expand the reach of its ExactVu micro-ultrasound system across independent practices, Veterans Affairs facilities, and integrated delivery networks. CIVCO Medical Solutions received CE marking in 2025 for TP Pivot Pro, a single-use transperineal needle guide that can reduce adoption barriers for smaller facilities. FDA clearance, CE marking under the EU Medical Device Regulation, and ISO 13485 certification remain significant barriers to entry. Although combined market-share data are not available, the market structure supports a moderate concentration assessment.

Prostate Biopsy Industry Leaders

  1. Becton, Dickinson and Company

  2. Boston Scientific Corporation

  3. Siemens Healthineers AG

  4. Koninklijke Philips N.V.

  5. Cook Group Incorporated

  6. *Disclaimer: Major Players sorted in no particular order

Prostate Biopsy Market Companies Covered in this Report

  • Argon Medical Devices
  • B. Braun
  • Beckton Dickinson
  • Biobot Surgical Pte. Ltd.
  • Boston Scientific
  • Canon
  • Cook Group
  • ESAOTE S.p.A.
  • Exact Imaging Inc.
  • Focal Healthcare Inc.
  • FUJIFILM
  • GE HealthCare Technologies Inc.
  • KOELIS SAS
  • Koninklijke Philips
  • MedCom GmbH
  • Medtronic
  • Siemens Healthineers

Recent Industry Developments in Prostate Biopsy Market

  • January 2026: CMS implemented nine new CPT Category I codes for prostate biopsy and retired CPT code 55700. The new codes differentiated transrectal, transperineal, in-bore MRI-guided, and MRI-ultrasound fusion-guided procedures, with imaging guidance bundled into each code; CPT 55713 and 55714 received higher ambulatory payment classifications.
  • December 2025: Cleveland Diagnostics received PMA approval for IsoPSA, a blood-based in vitro diagnostic test for men aged 50 years or older with elevated PSA levels. The NCCN 2025 Early Detection Guideline included the test, and Medicare and an increasing number of commercial payers covered it to help reduce unnecessary U.S. prostate biopsies.
  • November 2025: EAU-EANM-ESTRO-ESUR-ISUP-SIOG published the 2026 Prostate Cancer Guidelines, Part I, formalizing risk-adapted MRI-based strategies. The guidelines recommended pre-biopsy multiparametric MRI with targeted and regional biopsies, introduced a five-tier EAU classification system, and confirmed active surveillance for eligible low- and intermediate-risk cases.
  • July 2025: Royal Philips received FDA 510(k) clearance for the latest UroNav MRI-ultrasound fusion navigation system. The system added an annotation workflow for focal therapy planning and delivery using DynaCAD Urology, while Northwell Health reported a 30% improvement in high-risk prostate cancer diagnosis versus standard biopsy.

Table of Contents for Prostate Biopsy Industry Report

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET LANDSCAPE

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prostate Cancer Incidence and Biopsy Confirmation Demand
    • 4.2.2 Pre-Biopsy mpMRI Adoption and Targeted Sampling
    • 4.2.3 Shift Toward Transperineal Biopsy to Reduce Infection Risk
    • 4.2.4 Dedicated Reimbursement Codes for Fusion and Transperineal Biopsy
    • 4.2.5 AI-Assisted Lesion Detection and Prostate Volume Measurement
    • 4.2.6 Compact and Local-Anesthesia-Compatible Workflows
  • 4.3 Market Restraints
    • 4.3.1 High Capital Cost and MRI Infrastructure Dependence
    • 4.3.2 Shortage of mpMRI-Experienced Radiologists and Urologists
    • 4.3.3 Operator Variability and Lack of Consensus on Optimal Sampling Strategy
    • 4.3.4 Reprocessing, Sterility, and Workflow Burden in Transperineal Programs
  • 4.4 Value/Supply-Chain Analysis
  • 4.5 Regulatory Landscape
  • 4.6 Technological Outlook
  • 4.7 Porter's Five Forces Analysis
    • 4.7.1 Threat of New Entrants
    • 4.7.2 Bargaining Power of Suppliers
    • 4.7.3 Bargaining Power of Buyers
    • 4.7.4 Threat of Substitutes
    • 4.7.5 Competitive Rivalry

5. MARKET SIZE AND GROWTH FORECASTS (VALUE, USD)

  • 5.1 By Biopsy Type
    • 5.1.1 Prostate Needle Biopsy
    • 5.1.2 Prostate Liquid Biopsy
  • 5.2 By Guidance Technology
    • 5.2.1 Ultrasound-Guided Biopsy
    • 5.2.2 MRI-Guided Biopsy
    • 5.2.3 MRI-Ultrasound Fusion-Guided Biopsy
    • 5.2.4 Cognitive Fusion-Guided Biopsy
    • 5.2.5 CT-Guided Biopsy
    • 5.2.6 Other Guidance Technologies
  • 5.3 By Product Type
    • 5.3.1 Biopsy Needles
    • 5.3.2 Biopsy Guns and Instruments
    • 5.3.3 Biopsy Guidance and Navigation Systems
    • 5.3.4 Biopsy Accessories and Consumables
    • 5.3.5 Other Product Types
  • 5.4 By End User
    • 5.4.1 Hospitals
    • 5.4.2 Ambulatory Surgical Centers
    • 5.4.3 Diagnostic and Imaging Centers
    • 5.4.4 Urology Clinics and Physician Offices
    • 5.4.5 Other End Users
  • 5.5 By Geography
    • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
    • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
    • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 India
    • 5.5.3.3 Japan
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
    • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
    • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
    • 6.3.1 Argon Medical Devices, Inc.
    • 6.3.2 B. Braun Melsungen AG
    • 6.3.3 Becton, Dickinson and Company
    • 6.3.4 Biobot Surgical Pte. Ltd.
    • 6.3.5 Boston Scientific Corporation
    • 6.3.6 Canon Medical Systems Corporation
    • 6.3.7 Cook Group Incorporated
    • 6.3.8 ESAOTE S.p.A.
    • 6.3.9 Exact Imaging Inc.
    • 6.3.10 Focal Healthcare Inc.
    • 6.3.11 FUJIFILM Corporation
    • 6.3.12 GE HealthCare Technologies Inc.
    • 6.3.13 KOELIS SAS
    • 6.3.14 Koninklijke Philips N.V.
    • 6.3.15 MedCom GmbH
    • 6.3.16 Medtronic plc
    • 6.3.17 Siemens Healthineers AG

7. MARKET OPPORTUNITIES AND FUTURE OUTLOOK

  • 7.1 White-Space and Unmet-Need Assessment

Global Prostate Biopsy Market Report Scope

As per the scope of the report, a prostate biopsy is a medical procedure that removes small tissue samples from the prostate gland so they can be examined under a microscope for cancer or other cellular abnormalities. 

The prostate biopsy market is segmented by biopsy type, guidance technology, product type, end user, and geography. By biopsy type, the market is segmented into prostate needle biopsy and prostate liquid biopsy. By guidance technology, the market is segmented into ultrasound-guided biopsy, MRI-guided biopsy, MRI-ultrasound fusion-guided biopsy, cognitive fusion-guided biopsy, CT-guided biopsy, and other guidance technologies. By product type, the market includes biopsy needles, biopsy guns and instruments, biopsy guidance and navigation systems, biopsy accessories and consumables, and other product types. By end user, the market is segmented into hospitals, ambulatory surgical centers, diagnostic and imaging centers, urology clinics and physician offices, and other end users. By geography, the market is analyzed across North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers market sizes and forecasts in terms of value (USD) for the above segments.

Segmentation Overview

By Biopsy Type
Prostate Biopsy Market segmentation breakdown
Prostate Needle Biopsy
Prostate Liquid Biopsy
By Guidance Technology
Prostate Biopsy Market segmentation breakdown
Ultrasound-Guided Biopsy
MRI-Guided Biopsy
MRI-Ultrasound Fusion-Guided Biopsy
Cognitive Fusion-Guided Biopsy
CT-Guided Biopsy
Other Guidance Technologies
By Product Type
Prostate Biopsy Market segmentation breakdown
Biopsy Needles
Biopsy Guns and Instruments
Biopsy Guidance and Navigation Systems
Biopsy Accessories and Consumables
Other Product Types
By End User
Prostate Biopsy Market segmentation breakdown
Hospitals
Ambulatory Surgical Centers
Diagnostic and Imaging Centers
Urology Clinics and Physician Offices
Other End Users
By Geography
Prostate Biopsy Market segmentation breakdown
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Prostate Biopsy Market segmentation breakdown
By Biopsy Type Prostate Needle Biopsy
Prostate Liquid Biopsy
By Guidance Technology Ultrasound-Guided Biopsy
MRI-Guided Biopsy
MRI-Ultrasound Fusion-Guided Biopsy
Cognitive Fusion-Guided Biopsy
CT-Guided Biopsy
Other Guidance Technologies
By Product Type Biopsy Needles
Biopsy Guns and Instruments
Biopsy Guidance and Navigation Systems
Biopsy Accessories and Consumables
Other Product Types
By End User Hospitals
Ambulatory Surgical Centers
Diagnostic and Imaging Centers
Urology Clinics and Physician Offices
Other End Users
By Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
India
Japan
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

What is driving growth in the prostate biopsy market?

Rising prostate cancer diagnoses, greater use of pre-biopsy MRI, transperineal procedures, and clearer reimbursement for advanced guidance are supporting growth. The report projects a 7.66% CAGR from 2027 to 2032.

What is the projected value of the prostate biopsy market by 2032?

The prostate biopsy market is projected to reach USD 3.18 billion by 2032, increasing from USD 2.20 billion in 2027.

Which biopsy type has the largest revenue share?

Prostate needle biopsy held 85.67% of revenue in 2026 because tissue histopathology remains central to cancer confirmation, grading, and risk stratification.

Which guidance technology is growing fastest?

MRI-ultrasound fusion-guided biopsy is forecast to grow at a 10.12% CAGR through 2032 as providers adopt more targeted sampling pathways.

Why are transperineal prostate biopsies gaining use?

Transperineal biopsy is gaining use because it can lower infection risk and can be performed under local anesthesia in appropriate outpatient settings.

Which region is expected to grow fastest?

Asia-Pacific is forecast to grow at a 9.88% CAGR through 2032, supported by expanding screening, healthcare investment, and aging populations.

Page last updated on: